Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading T2 Biosystems Inc chart...

About the Company

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www

CEO

John Sperzel

Exchange

NASDAQ

Website

http://www.t2biosystems.com/

$28M

Total Revenue

186

Employees

$17M

Market Capitalization

-0.53

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TTOO News

T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

17h ago, source:

This publication is the strongest demonstration to date of the clinical impact the T2Resistance Panel in a real-world hospital setting,” said John Sperzel, Chairman and CEO of T2 Biosystems. “We ...

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

6d ago, source:

LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing ...

TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance

6d ago, source:

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of T2 Biosystems (NASDAQ:TTOO) stock are rising higher after the ...

Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients

2y ago, source:

Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating ...

T2 Biosystems Receives Extension From Nasdaq to Comply With Listing Requirement

6d ago, source: 360dx

The firm must demonstrate compliance with the Nasdaq's market value of listed securities requirement on or before May 20.

T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

6d ago, source:

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...